This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

MEINZER ET AL.

APPLICATION NO:

FILED:

FOR: OIL-FREE PHARMACEUTICAL COMPOSITIONS CONTAINING

CYCLOSPORIN A

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants wish to call the Examiner's attention to the references cited on the attached forms PTO-1449 and PTO-892.

Some of the listed references are of record in parent Application No. 09/992,584 filed November 6, 2001, and copies are available therein.

Applicants wish to make of record the 14 references marked with an asterisk which are cited on attached forms PTO-1449 (sheets 1/9, 4/9, 5/9, 8/9, and 9/9) which are copied from grand-parent application 09/284,391 (now USP 6,475,519). Copies of these references are not enclosed since they are available to the Examiner in said grand-parent application.

Applicants wish to make of record Applications No. 09/690,400, October 17, 2000 (now USP 6,258,808); 09/668,677, September 22, 2000 (abandoned, now 09/738,104, December 15, 2000, pending); 09/637,260, August 11, 2000 (abandoned, now 10/427,861, May 1, 2003, pending); and 09/724,526, November 28, 2000 (now USP 6,503,526). A copy of each application was provided in said grand-parent application and is not enclosed.

Applicants also wish to make of record the reference newly cited on attached form PTO-1449, a copy of which is enclosed. The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO forms.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080

Gabriel Lopez
Attorney for Applicants
Reg. No. 28,440
(862) 778-7882

encl: PTO-1449 (16 sheets) and PTO-892 (1 sheet) + 1 ref

Date: 2/18/04

Notice of References Cited

Application/Control No.	Applicant(s)/Pate	nt Under Reexam
09/992,584	MEINZI	ER, ET AL
Examiner	Art Unit	
JAMES M. SPEAR	1615	Page 1 of 1

U.S. PATENT DOCUMENTS

	Document Number Country Code-Number-Kind Code	Date MM-YYYY¹	U.S. PATENT D		Classification ²	
A	6,475,519	11/2002	-	Meinzer, et al	424	456
В						
С						
D		· ·				
E						
F						
G				,		
н	·					
1				••		
J						
К						
L						
м						

FOREIGN PATENT DOCUMENTS

	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification ²
N					
0					
Р					
a					
R					
s				6	
 τ					

NON-PATENT DOCUMENTS

		Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
	U	
	v	
Ġ.	w	
	x	

² Classifications may be U.S. or foreign.

^{*} A copy of this reference is not being furnished with this Office action. See MPEP § 707.05(a).

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

EXAMINER

4-100-8388B
APPLICATION NO.
09/992,584
APPLICANT
MEINZER ET AL.
FILING DATE
NOVEMBER 6, 2001

Group 1615

·	•		U.S.	PATENT D	OCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FIL	ING DATE
	AA			,					
	AB								
	AC								
	AD								
	AE								
	AF								
	AG								
	АН	·					·		
	ΑI				٠.				
	AJ								
	AK								
	AL	·							
			FOREIG	N PATENT	DOCUMENTS				
	•	DOCUMENT NUMBER	DATE		OFFICE	CLASS	SUBCLASS	TRAN	NSLATION NO
	AM	WO 94/25068	11/10/94	PCT			10		
	AN	WO 95/22982	8/31/95	PCT					
	AO	WO 95/32726	12/7/95	PCT					
	AP	2,230,440	10/24/90	UK					
	AQ	·				i e			
		OTHER DOC	UMENTS (Including Aut	thor, Title, Date, Pertine	nt pages, E	tc.)		
	AR					•			
	AS.							- 20-	· ·
	AT							,	-

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOC 4-100-8388B/C1 APPLICATION NO.

APPLICANT MEINZER, ET AL. 35 U.S.C. 371 FILING DATE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DAT
	AA	3,288,824	11/29/66	Mahler et al.	260	410.6	
	·AB	3,813,345	5/28/74	Urton	252	312	
,	AC	3,954,967	5/4/76	Urton	424	81	
	AD	4,073,943	2/14/78	Wretlind et al.	424	358	
	AE	4,146,499	3/27/79	Rosano	252	186	
·	AF	4,156,719	5/29/79	Sezaki et al.	424	118	
	AG	4,388,307	6/14/83	Cavanak	424	177	• .
.,	АН	4,567,161	1/28/86	Posanski et al.	514	23	
	Al	4,571,926	2/25/86	Scully	53	525	
	Al	4,695,450	9/22/87	Bauer et al.	424	22	
	AJ	4,719,239	1/12/88	Muller et al.	514	785	2/22/85
	AK	4,794,000	12/27/88	Ecanow	424	457	1/8/87
	AL	4,797,272	1/10/89	Linn et al.	424	59	
	AM	6,258,808	7/10/01	Hauer et al	514	227	
	AN	4,803,081	2/7/89	Falk et al.	424	488	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
,	AM	1,171,125	11/19/69	United Kingdom				
-	AN	1,209,361	8/12/86	Canada				
Ŋ.	AO	61/249,918	11/7/86	Japan (see English Abst)			Ø	
٠.	ΑP	135,171	3/27/85	Europe :				
	AR	2,222,770	3/21/90	United Kingdom				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Anonymous, Research Disclosure, No. 21143, and Res. Discl. No. 21143, "Galenic compositions comprising cyclosporin A [CS-A], (1981)
АТ	Beyer et al., Pharmazie in unserer Zeit, No. 2, "Micro-emulsions", pp. 55-60 (1983) – (Translation)

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOC 4-100-8388B/C1 APPLICATION NO.

APPLICANT MEINZER, ET AL. **35 U.S.C. 371 FILING DATE**

EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
,	AA	4,797,273	1/10/89	Linn et al.	424	59	
	AB	4,798,823	1/17/89	Witzel	514	11	
	AC	4,835,002	5/30/89	Wolf et al.	426	590	
	AD	4,888,239	12/19/89	Brox	428	402.2	
	AE	4,914,188	4/3/90	Dumont et al.	530	317	
	AF	4,963,367	10/16/90	Ecanow	424	485	
	AG	4,996,193	2/26/91	Hewitt et al.	514	11	
	АН	5,037,653	8/6/91	Dawson	424	405	
	Al	5,047,396	9/10/91	Orban et al.	514	11	45.
	AJ	5,154,754	10/13/92	Damo et al.	71	79	
	AK-	5,342,625	8/1/94	Hauer et al.	424	455	
	AL	5,614,491	3/25/97	Walch et al.	514	11	
	AM	5,652,212	7/29/97	Cavanak et al.	514	11	
	AN	5,741,512	4/21/88	Hauer et al.	424	450	
	AO	5,759,997	6/2/98	Cavanak	514	11	
	AP	5,951,971	9/14/99	Kawashima et al.	424	78.04	
	AQ	5,962,019	10/5/99	Cho et al.	424	455	
	AR	5,977,066	11/2/99	Cavanak	514	11	
, , , , , , , , , , , , , , , , , , ,	AS	5,985,321	11/16/99	Brox et al.	424	451	
···	AT.	6,007,840	12/28/99	Hauer et al.	424	450	,
	AU	6,008,191	12/28/99	Singh et al.	514	9	
	AV	6,008,192	12/28/99	Al-Razzak et al.	514	11	

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
AW	170,623	2/5/86	Europe				
AX	2,098,865	12/1/82	United Kingdom				
AY	2,206,119	12/29/88	United Kingdom				
. AZ	2,209,671	5/24/89	United Kingdom		*		

Sheet 3 of 8

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCK NO 4-100-8388B/C1 APPLICATION NO.

APPLICANT
MEINZER, ET AL.
35 U.S.C. 371 FILING DATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN: YES	SLATION NO
	AA	2,211,848	7/12/89	United Kingdom				
,	AN	240789	5/1/46	Switzerland (see English Abst)				
	AO	2,553,661	4/26/85	France		·		
	AP ·	211,258	2/25/87	Europe				
	Q	256,856	2/24/88	Europe				
-		OTHER DOC	UMENTS (Including Author, Title, Date, Pertinent	pages, Etc	.)		
	AB	Bhargava et al., Pharr	naceutical T	echnology, pp.46,48,50,52,54, Ma	arch 1987			
	AC	Cavanak et al., Prog.	Allergy, Vol	I. 38, pp.65-72 (1986)				
	AD	Ekman, Lipids, Vol. 22	2, No. 9, pp.6	557-663 (1987)				
EXAMINE	ER	*		DATE CONSIDERED				

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOC 4-100-8388B/C1 APPLICATION NO.

APPLICANT MEINZER, ET AL. 35 U.S.C. 371 FILING DATE

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRA YES	NSLATIO NO
· AA	274,431	7/13/83	Europe				
/ AC	3,315,805	11/8/84	Germany (see English Abst)		·		
AD	314,689 B1	5/10/89	Europe				
AE	641,356	2/29/84	Switzerland (see English Abst)		· ;		
AF	86/02264	4/24/86	PCT .			×	
AF	87/01035	2/26/87	PCT				
AH	2 015 339A	9/12/79	United Kingdom				
ΑI	88/00059	1/14/88	PCT				
JJ	895,724	7/28/83	Belgium			\boxtimes	
AK	0 315 079	5/10/89	Europe				
AL	2 211 408	7/5/89	United Kingdom				
AM	93/20833	10/28/93	PCT				
AN	378 893	7/25/90	Europe				
AO	91/08676	6/27/91	PCT				
AP	2 221 157	1/31/90	United Kingdom				
/ AQ	2 228 198	8/22/90	United Kingdom				
AR	2 224 205	5/2/90	United Kingdom				
AS	2 218 334	11/15/89	United Kingdom				
AT	361 928	4/4/90	Europe				
AU	2 230 440	10/24/90	United Kingdom				
AV	90/08537	8/9/90	PCT				
AW			:				

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKS NO 4-100-8388B/C1 APPLICATION NO.

APPLICANT MEINZER, ET AL. 35 U.S.C. 371 FILING DATE

U.S. PATENT DOCUMENTS

		•					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,108,985	8/22/78	Ruegger et al.	424	177	
	AB	4,210,581	7/1/80	Ruegger et al.	260	112.5	
	AC .	4,220,641	9/2/80	Traber et al.	424	177	
	AD	4,390,548	6/28/83	Yamato et al.	424	321	
	AE	4,482,576	11/13/84	Boot et al.	426	603	
	AF	4,652,406	3/24/87	Lepper et al.	260	410.9	
	AG	4,990,337	2/5/91	Kurihara et al.	424	427	
	АН	5,051,402	9/24/91	Kurihara et al.	514	11	
	ΑI	5,206,219	4/27/93	Desai	514	3	
· · · · · · · · · · · · · · · · · · ·	AJ	5,338,761	8/16/94	Nakajima et al.	514	772	
	AK	5,441,738	8/15/95	Klein et al.	424	195.1	
	AL	5,525,590	6/11/96	Bollinger et al.	514	11	
	AM	5,639,724	6/17/97	Cavanak	514	11	
	AN	5,756,450	5/26/98	Hahn et al.	514	9	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSL YES	ATION NO
		*				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Ritschel et al., Pharmaceutical Research Vol. 5(10): Suppl. 108 PD 943 (1988)	
AS	Stupar et al., Goldschmidt Inforwist Essein., Vol. 52, pp. 22-28 (1982) translation	-
AT		

EXAMINER

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

• FORM PTO-1449
• (REV. 7,85)
• INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCK NO 4-100-8388B/C1 APPLICATION NO.

APPLICANT MEINZER, ET AL. 35 U.S.C. 371 FILING DATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Hahn, Biodegradable Tensides (1988)
AB	Jayakrishnan et al., J. Soc. Cosmet. Chem. Vol. 34, pp.335-350 (1983)
AD	Mubarak, Development and Testing of New Micro-emulsions (1982)
AE	Muller et al., Pharm. Ind., Vol. 50 (11), pp. 1301-1306 (1988) (translation)
AF	Muller et al., Pharm. Ind., Vol. 50(3), pp. 370-375 (1988) (translation)
AG	Pohler, Micro-Emulsion Gels Structural Investigations and Galenical Properties (1983)
АН	Remington's Pharmaceutical Sciences, 17th Edition, (A.R.Gennaro, , Ed.) Microemulsions, Chapte 20, pp. 298-299, Easton, Pennsylvania, (1985)
Al	Reymond et al., Pharmaceutical Research, Vol. 5(10), pp. 673-676 (1988)
AJ	Reymond et al., Pharmaceutical Research, Vol. 5(10): 677-679 (1988)
AK	Reymond, In Vitro In Vivo Model for the Absorption of Cyclosporin A (1986)
AL	Ritschel et al., Meth. Find.Exp. Clin. Pharmacol., Vol. 11(4):281-287 (1989)
AM	Ritschel et al., Meth.Find. Exp. Clin. Pharmacol., Vol. 12, pp.127-134 (1990)
AN	Ritschel, Meth. Find. Exp. Clin. Pharmacol., Vol. 13(3), pp. 205-220 (1991)
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7,-85) INFORMATION DISCLOSURE CITATION

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

(Use several sheets if necessary)

ATTY. DOC 4-100-8388B/C1 APPLICATION NO.

APPLICANT MEINZER, ET AL. **35 U.S.C. 371 FILING DATE**

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AC Takada et al., J. Pharmacobio-Dyn., Vol. 11, pp.80-87 (1988) AD Takada et al., J. Pharmacobio-Dyn., Vol. 8, pp.320-323 (1985) AE Takada et al., J. Pharmacobio-Dyn., Vol. 9, pp.156-160 (1986) AE Tarr et al., Pharmaceutical Research, Vol. 6(1):40-43 (1989) AG Yanagawa et al., J. Microencapsulation, Vol. 6(2), pp. 161-164 (1989) AG Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AI Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AK Prazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)			Takada et al., Pharmaceutical Research, Vol. 3(1), pp.48-51 (1986)
AC AD Takada et al., J. Pharmacobio-Dyn. Vol. 8, pp.320-323 (1985) AE Takada et al., J. Pharmacobio-Dyn., Vol. 9, pp.156-160 (1986) AF Tarr et al., Pharmaceutical Research, Vol. 6(1):40-43 (1989) AG Yanagawa et al., J. Microencapsulation, Vol. 6(2), pp. 161-164 (1989) AI Liegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH AI Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AJ Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AK Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		AB	
Takada et al., J. Pharmacobio-Dyn., Vol. 8, pp.320-323 (1985) AE Tarr et al., Pharmacobio-Dyn., Vol. 9, pp.156-160 (1986) AF Tarr et al., Pharmaceutical Research, Vol. 6(1):40-43 (1989) AG Yanagawa et al., J. Microencapsulation, Vol. 6(2), pp. 161-164 (1989) AG Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AJ Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AK Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)			Takada et al., J. Pharmacobio-Dyn., Vol. 11, pp.80-87 (1988)
AD AE Takada et al., J. Pharmacobio-Dyn., Vol. 9, pp.156-160 (1986) AF Tarr et al., Pharmaceutical Research, Vol. 6(1):40-43 (1989) AG Yanagawa et al., J. Microencapsulation, Vol. 6(2), pp. 161-164 (1989) AG Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AJ Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AK Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		AC	*
Takada et al., J. Pharmacobio-Dyn., Vol. 9, pp.156-160 (1986) AF Tarr et al., Pharmaceutical Research, Vol. 6(1):40-43 (1989) AG Yanagawa et al., J. Microencapsulation, Vol. 6(2), pp. 161-164 (1989) AI Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AI Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AF Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		ΔD	Takada et al., J. Pharmacobio-Dyn. Vol. 8, pp.320-323 (1985)
AF Tarr et al., Pharmaceutical Research, Vol. 6(1):40-43 (1989) AG Yanagawa et al., J. Microencapsulation, Vol. 6(2), pp. 161-164 (1989) AG Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AI Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AJ Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		AD	
AF Tarr et al., Pharmaceutical Research, Vol. 6(1):40-43 (1989) AG Yanagawa et al., J. Microencapsulation, Vol. 6(2), pp. 161-164 (1989) Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AI Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AK Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		ΔF	Takada et al., J. Pharmacobio-Dyn., Vol. 9, pp.156-160 (1986)
AF Yanagawa et al., J. Microencapsulation, Vol. 6(2), pp. 161-164 (1989) Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AI Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AK Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)	· · · ·		·
AG Yanagawa et al., J. Microencapsulation, Vol. 6(2), pp. 161-164 (1989) Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AI Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AJ Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		ΔF	Tarr et al., Pharmaceutical Research, Vol. 6(1):40-43 (1989)
AG AH Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AJ Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AJ Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		<i>,</i> "	
AH Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AJ Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AK Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		AG	Yanagawa et al., J. Microencapsulation, Vol. 6(2), pp. 161-164 (1989)
AH Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987) AJ Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AK Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)			
AJ Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AK Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)	:	АН	Ziegenmeyer et al., Acta Pharmaceutica Technologica, Vol. 26(4), pp.273-275 (1980) (translation)
AJ Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973) AK Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		•••	Ulman's Encyclopaedia of Industrial Pharmacy, Vol. A9, pp. 298-299 and 308-311 (1987)
AJ Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		AI	
AK Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944) AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.) Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		A 1	Carrigan et al., J. Pharm. Sci., Vol. 62, pp. 1476-1479 (1973)
AK Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)	-	AJ	
Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992) AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		AIZ	Frazer et al., J. Physiol., Vol. 103, pp. 306-316 (1944)
AL Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). AM The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		AN	
Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982). The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		ΔΙ	Drewe et al., Br. J. Clin. Pharmac., Vol. 33, pp. 39-43 (1992)
AM The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)		AL	
	ν,	АМ	Charley, Food Science, 2nd edition, pp. 224, 226, 228-229, John Wiley & Sons (1982).
AN			The Merck Index, 9th Edition, (M. Windhold, Ed.)Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)
		AN	·

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOC 4-100-8388B/C1 APPLICATION NO.

APPLICANT MEINZER, ET AL. 35 U.S.C. 371 FILING DATE

Sheet 8 of 8

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAI YES	NSLATION NO
AA	616190	1/18/49	United Kingdom				
AE	3 1 516 348	7/5/78	Great Britain				
· AC	97/34622	9/25/97	PCT				
· AE	589 843	3/30/94	Europe				
AE	44 12 201	11/10/94	Germany (see English Abst)				
AF	195 39 860	5/9/96	Germany (see English Abst)	·			
ÁC	G 170 623	2/5/86	Europe				
AH	1 2120935	12/14/83	United Kingdom				
Al	96/36316	11/21/96	PCT	·			
ÁJ	2098865	12/1/82	United Kingdom				
. Ak	61/280435	12/11/86	Japan (see English Abst)			\boxtimes	
ÁL	4,003,844	8/16/90	Germany (see English Abst)				
AN	M 327,280	8/9/89	Europe				
· AN	92/09299	6/11/92	PCT .		·		
ĀF	298 351	2/20/92	Germany (see English Abst)				
AC	2						
AF	₹						
AS	6						
ΑT	T						
AL	J						
AL			DATE CONSIDERED				

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 1 of 1

FORM P10-1440 (REV. 9-06)

> AI AJ AK AL

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Upe neveral sheets if necessary)

ATTY. DOCKET NO. 4-100-8388B APPLICATION NO. 09/992,584 APPLICANT MEINZER ET AL. FILING DATE NOVEMBER 6, 2001

Group 1615

EXAMINER **DOCUMENT NUMBER** DATE NAME CLASS **SUBCLASS** FILING DATE INITIAL AA 5,589,455 12/31/96 Woo 514 04/21/95 11 AB. 5,766,629 06/16/98 Cho et al. 424 455 03/21/96 . . AC 5,827,822 10/27/98 Floc'h et al. 514 11 03/25/96 AD 5,834,017 11/10/98 Cho et al. 424 455 08/25/95 ΑE AF AG AH

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	ISLATION NO
AM	WO 95/11039	04/27/95	WIPO (+ AU equiv.)			8	
AN	WO 97/00080	01/03/97	WIPO (+ AU equiv.)			Ň	
AO	WO 98/40051	09/17/98	WIPO				
AP	WO 98/40094	09/17/98	WIPO				
 AQ	738 604	08/23/43	DE			Ř	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Takada et al., "Development of a New Carrier for Cyclosporine A With Selectivity for Lymphatics", Transplant. Proc., Vol. XIX, No. 1, pp. 1711-1712 (1987).
<u> </u>	AS	Yasumura, Vol. 136, pp. 455-456 (1986) + translation.
	АТ	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-100-8388A/PCT
APPLICATION NO.
09/284,391
APPLICANT
MEINZER, ET AL.
35 U.S.C. 371 FILING DATE
April 13, 1999

Group 1615

U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DAT
	AA	3,288,824	11/29/66	Mahler et al.	260	410.6	
	AB	3,813,345	5/28/74	Urton	252	312	
	AC	3,954,967	5/4/76	Urton ·	424	78	
	AD	4,073,943	2/14/78	Wretlind et al.	424	358	
	AE	4,146,499	3/27/79	Rosano	252	186	(3)
	AF	4,156,719	5/29/79	Sezaki et al.	424	177	
	AG	4,388,307	6/14/83	Cavanak	424	177	
	АН	4,567,161	1/28/86	Posanski et al.	424	199	
	Al	4,571,926	2/25/86	Scully	53	525	· · · · · · · · · · · · · · · · · · ·
	Al	4,695,450	9/22/87	Bauer et al.	424	168	
	AJ	4,719,239	1/12/88	Muller et al.	514	785	2/22/85
	AK	4,794,000	12/27/88	Ecanow	424	457	1/8/87
٠.	AL	4,797,272	1/10/89	Linn et al.	424	59	
	AM	4,803,081	2/7/89	Falk, et al	424	488	<u> </u>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN	SLATION NO
	AM	1,171,125	11/19/69	United Kingdom				
	AN	1,209,361	8/12/86	Canada				
•	AO	61/249,918	11/7/86	Japan (see English Abst)			\boxtimes	
	AP	135,171	3/27/85	Europe				
•	AQ	2,222,770	3/21/90	United Kingdom				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Anonymous, Chemical Abstracts, 1981:625610 (95:225610K) "Galenic compositions comprising cyclosporin A [CS-A]", (1981)
莽	AS	Anonymous, Derwent Abstracts, 1981-88539D, [48], "Cialenic compsn. of cyclosporin-A for intravenous admin. – using reaction prod. of (hydrogenated) castor oil and ethylene oxide as carrier medium. Research Disclosure 0211043 (11/10/1981)
	АТ	Beyer et al., Pharmazie in unserer Zeit, Vol. 12(2): "Micro-emulsions", pp. 55-60 (1983) (English Equivalent) TBS
-XAMINI	FR	DATE CONSIDERED



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 4 of 9

ATTY. DOCKET NO. 4-100-8388A/PCT APPLICATION NO. 09/284,391 **APPLICANT** MEINZER, ET AL. 35 U.S.C. 371 FILING DATE April 13, 1999

Group 1615

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRA	NSLATION NO
AA	274,431	7/13/83	Europe		·		
米 AE	280,435	4/4/85	Japan (see English Abst)				
AC	3,315,805	11/4/84	Germany (see English Abst)				
AC	314,689	5/10/89	Europe				
AE	641,356	2/29/84	Switzerland (see English Abst)				
AF	8,602,264	4/24/86	PCT				
AF	87/01035	2/26/87	PCT				
. AF	2 015 339A	9/12/79	United Kingdom				
Al	88/00059	1/14/88	PCT	-			
(JJ	895,724	7/28/83	Belgium				
AK	0 315 079	5/10/89	Europe				
、 AL	2 211 408	7/5/89	United Kingdom		_		
· AN	93/20833	10/28/93	PCT				
AN	0 378 893	7/25/90	Europe	*			
AC	91/08676	6/27/91	PCT				
AP	2 221 157 A	1/31/90	United Kingdom				
AC	2 228 198 A	8/22/90	United Kingdom				
AR	2 224 205A	5/2/90	United Kingdom				
AS	2 218 334	11/15/89	United Kingdom				
AT	0 361 928	4/4/90	Europe		·		
AU	2 230 440A	10/24/90	United Kingdom				
. AV	90/08537	8/9/90	PCT				
AV				1		П	

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609 Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-100-8388A/PCT APPLICATION NO. 09/284,391 APPLICANT MEINZER, ET AL.

35 U.S.C. 371 FILING DATE April 13, 1999

Sheet 5 of 9

Group 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,108,985	8/78	Ruegger et al	514	11	
	AB	4,210,581	7/80	Ruegger et al.	530	321	
	AC	4,220,641 -	9/80	Traber et al.	514	11	
	AD	4,390,548	6/1993	Yamato et al	564	98	4
	AE	4,482,576	11/13/84	Boot et al.	426	603	
	AF	4,652,406	3/24/87	Lepper et al.	260	410.9	
	AG	4,990,337	2/5/91	Kurihara et al.	424	427	
	АН	5,051,402	9/24/91	Kurihara et al.	514	11	
	Al	5,206,219	4/27/93	Desai	514	3	
	AJ	5,338,761	8/16/94	Nakajima et al.	514	772	
	AK	5,441,738	8/15/95	Klein et al.	424	195.1	1
	AL	5,525,590	6/11/96	Bollinger et al.			
	AM	5,639,724	6/17/97	Cavanak	514	11	
	AN	5,756,450	5/26/98	Hahn et al.	514	9	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANS	NO NO
					_	
	٠					
·						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Ritschel, et al., Pharmaceutical Research Vol. 5(10): Suppl. 108 PD 943 (1988)
	AS	Stupar et al., Goldschmidt Inforwist Essein. Vol. 52: 22-28 (1982) translation
*	AT	Takada, Derwent Abstracts 87-024776/04 (JP61280435), (4/4/85)

EXAMINER

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 8 of 9

ATTY. DOCKET NO.
4-100-8388A/PCT
APPLICATION NO.
09/284,391
APPLICANT
MEINZER, ET AL.
35 U.S.C. 371 FILING DATE
April 13, 1999

Group 1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

*	AA	Derwent Abstract 90-255218/34, (DE4003844), 1989
*	AB	Derwent Abstract 86-335072, Mizushima, (JP61249918), 1986
*	AC	Derwent Abstract 87-024776, (JP61280435), 1986
*	AF	Derwent Abstract 92-216793/26, Orban et al, (WO92/09299) 1990
*	AG	Derwent Abstract 92-23516, Huettenrauch, "Prepn. of carrier-dependent pharmaceuticals – by dissolving active ingredient in lower polyfunctional alcohol, melting soln. with carrier materials and a long chain organic acid and filling into gelatin capsules."
¥	АН	Derwent Abstract 84-069426/12, Cavanak, (CH641356), 1984
	Al	The Merck Index, 9th Ed., Merck & Co., Inc., Rahway, NJ, p. 1017 (1976)
*	AJ	Derwent Abstract 94-341475, Fleck et al., (DE 4412201) 1994
K	AK	Derwent Abstract 96-231783, Olbrich et al., (DE 19539860) 1996
¥	AL	Derwent Abstract 84-282904 [46], Andrews et al, (DE 3315805)
*	AM	Derwent Abstract 49-44190, Reichstein, (CH240789) 1946
XAMINER		DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
4-100-8388A/PCT
APPLICATION NO.
09/284,391
APPLICANT
MEINZER, ET AL.
35 U.S.C. 371 FILING DATE
April 13, 1999

Group 1615

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRA	NSLATION
							YES	NO
	AA	616190	1/18/49	United Kingdom				
,	AB	1 516 348	7/5/78	Great Britain				
`	AC	97/34622	9/25/97	PCT .				· ·
	AD	589 843	3/30/94	Europe		-		
	AE	44 12 201	11/10/94	Germany (see English Abst)				
	AF	195 39 860	5/9/96	Germany (see English Abst)				
	AG	170 623	2/1986	Europe				
	АН	2120935	12/1983	United Kingdom				
	Al	WO 96/36316	11/21/96	PCT				
	AJ	2098865	12/1982	United Kingdom				
K	AK	87 024776	4/4/85	Japan				
	AL	4,003,844	8/16/90	Germany (see English Abst)				
	AM	327,280	8/9/89	Europe				
•	AN	WO 92/09299	6/11/92	PCT (see English Abst)				
	AO							
	AP		,					
	AQ					•		
	AR				·			
	AS	·						
	AT							
	AU							
EXAMIN	EXAMINER			DATE CONSIDERED				

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 1 of 1

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-100-8388C APPLICATION NO.

APPLICANT MEINZER ET AL. FILING DATE

Group

			U.S.	PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILI	NG DATE
	AA	6,486,124 B2	11/26/02	Olbrich et al.				
	AB		*· -					
	AC							
	AD				a e			
	ΑE			•				
	AF							
	AG							
	АН							
	Al							
	AJ							
	AK							
	AL	0		·		_		
			FOREIG	ON PATENT DOCUMENTS			•	
	·	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	AM	·						
	AN							
	AO							
	AP							
	AQ							
		OTHER DOO	UMENTS	(Including Author, Title, Date, Per	tinent pages, E	tc.)	, .	·•
	AR							
								
	AS							
	AT							
EXAMINI	ER	L		DATE CONSIDERED				

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.